BR112017021608A2 - ésteres de glicosaminoglicano, processos para sua preparação e seu uso em formulações oftálmicas - Google Patents

ésteres de glicosaminoglicano, processos para sua preparação e seu uso em formulações oftálmicas

Info

Publication number
BR112017021608A2
BR112017021608A2 BR112017021608A BR112017021608A BR112017021608A2 BR 112017021608 A2 BR112017021608 A2 BR 112017021608A2 BR 112017021608 A BR112017021608 A BR 112017021608A BR 112017021608 A BR112017021608 A BR 112017021608A BR 112017021608 A2 BR112017021608 A2 BR 112017021608A2
Authority
BR
Brazil
Prior art keywords
preparation
processes
ophthalmic formulations
glycosaminoglycan
glycosaminoglycan esters
Prior art date
Application number
BR112017021608A
Other languages
English (en)
Portuguese (pt)
Inventor
Baricordi Nikla
Merighi Roberto
Original Assignee
Hyalblue S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyalblue S R L filed Critical Hyalblue S R L
Publication of BR112017021608A2 publication Critical patent/BR112017021608A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR112017021608A 2015-04-07 2016-04-07 ésteres de glicosaminoglicano, processos para sua preparação e seu uso em formulações oftálmicas BR112017021608A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI20150102 2015-04-07
PCT/IB2016/051960 WO2016162809A1 (en) 2015-04-07 2016-04-07 Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use

Publications (1)

Publication Number Publication Date
BR112017021608A2 true BR112017021608A2 (pt) 2018-07-03

Family

ID=53719816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021608A BR112017021608A2 (pt) 2015-04-07 2016-04-07 ésteres de glicosaminoglicano, processos para sua preparação e seu uso em formulações oftálmicas

Country Status (12)

Country Link
US (1) US10328097B2 (cg-RX-API-DMAC10.html)
EP (1) EP3280396B1 (cg-RX-API-DMAC10.html)
JP (1) JP6847091B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180002674A (cg-RX-API-DMAC10.html)
CN (1) CN107636020A (cg-RX-API-DMAC10.html)
AU (1) AU2016244391B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017021608A2 (cg-RX-API-DMAC10.html)
CA (1) CA2981861A1 (cg-RX-API-DMAC10.html)
ES (1) ES2888648T3 (cg-RX-API-DMAC10.html)
MA (1) MA41912A (cg-RX-API-DMAC10.html)
RU (1) RU2726192C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016162809A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000012535A1 (it) * 2020-05-27 2021-11-27 Stefano Colombo Composizione oftalmica a base di acido ialuronico per la protezione dai danni causati dall’inquinamento ambientale
WO2022094695A1 (en) 2020-11-03 2022-05-12 Institut National De La Recherche Scientifique A method and a system for compressed ultrafast tomographic imaging
CN116284495B (zh) * 2023-03-20 2024-08-30 润辉生物技术(威海)有限公司 全反式维甲酸低分子透明质酸酯衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1281877B1 (it) * 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici
ITTS20010017A1 (it) * 2001-07-17 2003-01-17 Ct Ricerche Polytech Soc Coop Esteri polisaccaridici di acido retinoico.
ITMI20022745A1 (it) * 2002-12-23 2004-06-24 Coimex Scrl United Companies Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione.
ITMI20030043A1 (it) * 2003-01-14 2004-07-15 Coimex S C R L United Companies Uso di esteri retinoici dell'acido ialuronico in cellule
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
ITMI20062134A1 (it) * 2006-11-08 2008-05-09 Cbb Net S A Preparaziobne di esteri della diacereina con acido ialuronico e loro formulazioni per l'impiego farmaceutico
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
CA2886115A1 (en) * 2012-10-02 2014-04-10 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes

Also Published As

Publication number Publication date
EP3280396A1 (en) 2018-02-14
AU2016244391A1 (en) 2017-11-23
JP2018510962A (ja) 2018-04-19
CA2981861A1 (en) 2016-10-13
ES2888648T3 (es) 2022-01-05
AU2016244391B2 (en) 2020-11-19
US10328097B2 (en) 2019-06-25
CN107636020A (zh) 2018-01-26
RU2017138283A (ru) 2019-05-07
MA41912A (fr) 2018-02-13
WO2016162809A1 (en) 2016-10-13
JP6847091B2 (ja) 2021-03-24
RU2017138283A3 (cg-RX-API-DMAC10.html) 2019-09-30
EP3280396B1 (en) 2021-06-23
RU2726192C2 (ru) 2020-07-09
US20180117077A1 (en) 2018-05-03
KR20180002674A (ko) 2018-01-08

Similar Documents

Publication Publication Date Title
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112016002233A2 (pt) composições de adoçante
BR112016014293A2 (pt) região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX382518B (es) Antigenos de citomegalovirus y su uso.
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112016023729A2 (pt) espelho de veículo e método para a fabricação de tal espelho
CO7170174A2 (es) Formulación farmacéutica
BR112018002427A2 (pt) terapias de combinação para tratamento do câncer
BR112016013800A2 (pt) Composições e métodos para reduzir alérgenos de gatos no ambiente
BR112017015452A2 (pt) formulação farmacêutica
BR112016022214A2 (pt) rnase para uso no tratamento ou prevenção de infecções virais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2717 DE 31-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.